Margaret
K. Kyle
Assistant
Professor
London
Business School
Regent's
Park
London
NW1 4SA
United
Kingdom
+44
20 7000 8727
Working Papers
Investments in
Pharmaceuticals Before and After TRIPS, with Anita McGahan, August
2008. (revision requested by Review of Economics and Statistics)
Strategic
Responses to Parallel Trade, October 2008.
The
Timing of Licensing: Theory and Empirics, with Marie-Laure Allain and Emeric
Henry, November 2008.
The
Influence of TRIPS on Global Trade in Pharmaceuticals, 1993-2006, with Mercedes
Delgado and Anita McGahan, February 2008.
Publications
in refereed journals
Does
Re-importation Reduce Price Differences for Prescription Drugs? Lessons from the European Union, with
Jennifer Allsbrook and Kevin Schulman, Health Services Research August 2008, 43(4),
1308-1324.
Would
Greater Price Transparency and Uniformity Benefit Poor Patients? with David
Ridley, Health Affairs Sept/Oct 2007, 26(5), 1384-1391.
Generic
Competition and Market Exclusivity Periods in Pharmaceuticals, with Henry
Grabowski, Managerial and Decision Economics, June-August 2007,
28(4-5), 491-502.
Pharmaceutical
Price Controls and Entry Strategies, Review of Economics and
Statistics,
February 2007, 89(1), 88-99.
The
Role of Firm Characteristics in Pharmaceutical Product Launches, RAND
Journal of Economics, Autumn 2006, 37(3), 602-618.
Surviving
the Gales of Creative Destruction: The Determinants of Product Turnover,
(2006) with John M. de Figueiredo, Strategic Management Journal 27(3), 241-264.
Objective
and Self-Reported Work Performance Measures: A Comparative Analysis, with Glenn
Pransky, Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan Tortorice
(2006), International Journal of Productivity & Performance Management 55(5), 390-399.
Public
& Private Spillovers, Location, and the Productivity of Pharmaceutical
Research, with Jeff Furman, Iain Cockburn, and Rebecca Henderson,
December 2005. Forthcoming in Annales d'Economie et Statistique.
Deregulating Direct-to-consumer Marketing of
Prescription Drugs: Effects on Prescription and Over-the-counter Sales
with Ernst R. Berndt and Davina Ling (2002), Journal of Law and Economics 44 (3), 691-723.
Measuring
health impacts on work performance: Comparing subjective and objective reports,
with Glenn Pransky, Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan
Tortorice (2002), Value in Health 5(6), 448-449.
Other
Mergers
and Alliances in Pharmaceuticals: Effects on Innovation and R&D
Productivity, with Henry Grabowski, in The Economics of Corporate Governance
and Mergers,
edited by Klaus Peter Gugler and B. Burcin Yurtoglu (Cheltenham, UK: Edward
Elgar Publishing, 2008).
Innovation in the Pharmaceutical Industry, report
prepared for the National Endowment for Science, Technology and the Arts, May
2008.
Product
Launch Decisions by Dominant and Fringe Firms with John M. de Figueiredo, Best
Paper Proceedings of the Academy of Management, 2005.
Does Locale Affect R&D Productivity? The Case of Pharmaceuticals,
Federal Reserve Bank of San Francisco Economic Letter, Number 2004-32, Nov. 12,
2004.
The Long Shadow
of Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?
with Ernst R. Berndt and Davina Ling, in NBER Conference Volume on Scanner
Data and Price Indexes, edited by Robert Feenstra and Matthew Shapiro (Chicago: University of
Chicago Press, 2003).
Did
U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did it Matter to
Bank Lending? with Allen N. Berger and Joseph M. Scalise in Prudential
Supervision: What Works and What Doesn't, edited by Frederic Mishkin (Chicago:
University of Chicago Press, 2001).